Glycan-based Chemosensitization Therapy

About AccuDava

AccuDava is a private, pre-revenue diagnostics and therapeutic development company tackling a critical unmet need in oncology: platinum chemotherapy resistance. The company has developed a novel diagnostic method, initially validated in ovarian and lung cancers, designed to accurately identify non-responsive patients before treatment begins. Supported by multiple NIH SBIR grants and a strong IP portfolio, AccuDava aims to personalize cancer treatment decisions and is concurrently developing a glycan-based technology to circumvent resistance. Its leadership combines scientific expertise in glycobiology and oncology with business development acumen.

Therapeutic Areas